Last reviewed · How we verify
NCT06248957: SAID
SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION
trial testing Immunomodulation in Immunodeficiency in 500 participants. Currently enrolling.
31 December 2030
Quick facts
| Lead sponsor | Karolinska Institutet |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 January 2024 |
| Primary completion | 31 December 2030 |
| Estimated completion | 31 December 2031 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Immunomodulation — full drug profile →
Conditions studied
- Immunodeficiency — all drugs for Immunodeficiency →
- Autoimmune Diseases — all drugs for Autoimmune Diseases →
- Autoinflammatory Syndrome — all drugs for Autoinflammatory Syndrome →
- Allergy — all drugs for Allergy →
Sponsor
Karolinska Institutet
Who can join
Eligibility, any sex, with Immunodeficiency or Autoimmune Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the SAID study is to create a national resource in Sweden to enable comprehensive immunological analyses of an extremely complex and clinically challenging group of individuals with variable forms of immune system dysregulation. We hope to establish a biobank of primarily blood and fecal samples from children and adults, with confirmed or suspected immune dysregulation, as well as age- and sex- matched healthy controls, for comparisons of immune cell/mediator alongside various clinical presentations of these immunological diseases as well as microbiome samples as possible a possible modifier of clinical presentations. The project will also include the establishment of a national database with deep immunological data, treatment and clinical outcomes for these patients, accessible to participating researchers and clinicians.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06248957
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Immunomodulation
Trials testing the same drug.
- NCT07277439 — Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma · Phase 2 · recruiting
Other recruiting trials for Immunodeficiency
Currently open trials in the same condition.
- NCT06612515 — Vaccine-induced Immunity in Immunocompromised Patients · recruiting
- NCT05907746 — Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Defici · Phase 2 · active not recruiting
- NCT05587894 — OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Tri · Phase 2 · recruiting
- NCT07406217 — OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients · Phase 2 · recruiting
- NCT05027945 — A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked · Phase 2 · recruiting
Other Karolinska Institutet trials
Trials by the same sponsor.
- NCT06359262 — Evaluating the Hope@School Prevention Program · NA · not yet recruiting
- NCT07289490 — Bilateral vs Unilateral Inguinal Hernia Repairs With an Asymptomatic Inguinal Hernia in Bilateral Hernias · NA · not yet recruiting
- NCT06894264 — Emotion Processing and Regulation in People With Intellectual Disability · NA · not yet recruiting
- NCT07494266 — Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited · NA · not yet recruiting
- NCT07442032 — Cardiovascular Phenotypes in Sepsis · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06248957 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Karolinska Institutet
- Last refreshed: 8 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06248957.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing